Vivos publishes peer-reviewed data on PrecisionGel thermogel
Vivos Inc., the Washington-based radionuclide therapy developer, has announced the peer-reviewed publication of characterisation data for its PrecisionGel thermogel polymer platform in the Journal of Drug Delivery Science and Technology, an Elsevier publication covering drug formulation and controlled release.
The paper, produced in collaboration with specialist polymer manufacturer Akina Inc., summarises three years of development research examining the thermogel's biomolecular release properties across a range of concentrations and polymer compositions. PrecisionGel is a poly(lactide-co-glycolide)-graft-(polyethylene glycol) material that remains liquid at room temperature and gels at body temperature, allowing localised retention of therapeutic agents after injection.
Clinical and licensing significance
PrecisionGel serves as the polymer carrier component in two Vivos products: IsoPet, an Yttrium-90 treatment for tumours in animals that holds FDA commercial authorisation in the United States, and RadioGel, a human oncology application that carries FDA Breakthrough Device designation. The company says the publication will strengthen the scientific record supporting clinical programmes currently advancing at Mayo Clinic, the Health Care Global Cancer Centre in India, and a number of unnamed international sites.
Chief executive Michael K. Korenko said the peer-reviewed venue was precisely where potential licensing partners look when evaluating platform technologies. "This publication validates PrecisionGel in exactly the venue those companies read," he said. "It also strengthens the scientific foundation for our clinical programs at Mayo Clinic and internationally, where regulatory authorities and hospital ethics committees rely on the same literature to evaluate novel platforms."
Beyond its role in Vivos's own pipeline, PrecisionGel is positioned by the company as a licensable universal drug delivery carrier. Several pharmaceutical and industrial companies are reported to be testing it for their own agent-release applications, and Vivos says the Elsevier publication materially improves its standing as a licensing candidate.
Regulatory and competitive context
The publication carries particular weight for Vivos's international expansion plans. The company identifies the United Kingdom, Australia, the European Union, Japan and India as priority regulatory markets, and notes that authorities in each jurisdiction place significant weight on indexed peer-reviewed literature when evaluating novel device platforms.
The localised radionuclide delivery space remains a relatively specialised corner of oncology, with most commercial activity concentrated in systemic radiopharmaceuticals. Companies pursuing injectable depot approaches for solid tumours face a comparatively clear competitive field at present, though academic and industry interest in local tumour ablation technologies has been growing. For Vivos, the more immediate commercial question is whether the PrecisionGel licensing programme can generate near-term revenue to complement the longer development timeline of RadioGel's human clinical programme. Investors will be watching for named licensing partners and updated clinical milestones from the Mayo Clinic collaboration as the next substantive signals of progress.